| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CMTM6 |
| Uniprot No | Q9NX76 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-183aa |
| 氨基酸序列 | MENGAVYSPTTEEDPGPARGPRSGLAAYFFMGRLPLLRRVLKGLQLLLSLLAFICEEVVSQCTLCGGLYFFEFVSCSAFLLSLLILIVYCTPFYERVDTTKVKSSDFYITLGTGCVFLLASIIFVSTHDRTSAEIAAIVFGFIASFMFLLDFITMLYEKRQESQLRKPENTTRAEALTEPLNA |
| 分子量 | 46.8 KDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于重组人CMTM6蛋白的参考文献摘要概括：
1. **《CMTM6 maintains the expression of PD-L1 and regulates anti-tumor immunity》**
- **作者**: Burr ML, et al. (2017. Nature)
- **摘要**: 研究发现CMTM6通过稳定PD-L1蛋白表达，促进肿瘤免疫逃逸。重组人CMTM6蛋白的体外实验证实其与PD-L1直接互作，抑制溶酶体降解途径，为癌症免疫治疗提供新靶点。
2. **《Structural basis of CMTM6-mediated PD-L1 regulation》**
- **作者**: Zhang X, et al. (2020. Cell Research)
- **摘要**: 通过重组人CMTM6蛋白的结晶分析，揭示了其与PD-L1结合的分子结构域及作用机制，阐明CMTM6通过二聚化保护PD-L1不被泛素化降解的结构基础。
3. **《Generation and Functional Characterization of Recombinant CMTM6 Protein for Immune Checkpoint Studies》**
- **作者**: Li Y, et al. (2018. Scientific Reports)
- **摘要**: 研究报道了重组人CMTM6蛋白在HEK293细胞中的表达纯化方法，并验证其在T细胞抑制实验中的功能，证实重组蛋白可增强PD-L1介导的免疫抑制活性。
*注：若需更早期或特定方向的研究，可补充检索年份及关键词进一步筛选。*
CMTM6 (CKLF-like MARVEL transmembrane domain-containing 6) is a member of the chemokine-like factor (CKLF) superfamily, characterized by a conserved MARVEL domain implicated in membrane-associated processes. Originally identified in immune and epithelial tissues, CMTM6 regulates protein stability and trafficking, notably serving as a key post-translational stabilizer of programmed death-ligand 1 (PD-L1), a critical immune checkpoint molecule in cancer. By binding to PD-L1 and preventing its lysosomal degradation, CMTM6 modulates tumor immune evasion, making it a potential target for cancer immunotherapy.
Recombinant human CMTM6 protein is engineered using expression systems (e.g., HEK293 or E. coli) to produce functional or tag-fused variants for in vitro studies. It aids in elucidating CMTM6-PD-L1 interactions, immune regulation mechanisms, and therapeutic screening. Research highlights its role in tumor microenvironments, chemoresistance, and viral infection responses, revealing broad functional versatility beyond oncology. Its recombinant form is pivotal for structural analysis, antibody development, and deciphering pathways in immune-oncology, offering translational avenues for combination therapies targeting PD-1/PD-L1 axis resistance. Studies using recombinant CMTM6 also explore its interplay with other immune checkpoints, enhancing understanding of tumor-immune dynamics.
×
